Advertisement
Research Article

SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis

  • Robert T. Jacobs mail,

    bob.jacobs@scynexis.com

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Bakela Nare,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Stephen A. Wring,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Matthew D. Orr,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Daitao Chen,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Jessica M. Sligar,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Matthew X. Jenks,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Robert A. Noe,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Tana S. Bowling,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Luke T. Mercer,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Cindy Rewerts,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Eric Gaukel,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Jennifer Owens,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Robin Parham,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Ryan Randolph,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Beth Beaudet,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Cyrus J. Bacchi,

    Affiliation: Haskins Laboratory, Pace University, New York, New York, United States of America

    X
  • Nigel Yarlett,

    Affiliation: Haskins Laboratory, Pace University, New York, New York, United States of America

    X
  • Jacob J. Plattner,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Yvonne Freund,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Charles Ding,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Tsutomu Akama,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Y.-K. Zhang,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Reto Brun,

    Affiliation: Swiss Tropical and Public Health Institute, Basel, Switzerland

    X
  • Marcel Kaiser,

    Affiliation: Swiss Tropical and Public Health Institute, Basel, Switzerland

    X
  • Ivan Scandale,

    Affiliation: Drugs for Neglected Diseases initiative, Geneva, Switzerland

    X
  • Robert Don

    Affiliation: Drugs for Neglected Diseases initiative, Geneva, Switzerland

    X
  • Published: June 28, 2011
  • DOI: 10.1371/journal.pntd.0001151

About the Authors

Robert T. Jacobs, Bakela Nare, Stephen A. Wring, Matthew D. Orr, Daitao Chen, Jessica M. Sligar, Matthew X. Jenks, Robert A. Noe, Tana S. Bowling, Luke T. Mercer, Cindy Rewerts, Eric Gaukel, Jennifer Owens, Robin Parham, Ryan Randolph, Beth Beaudet
SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America
Cyrus J. Bacchi, Nigel Yarlett
Haskins Laboratory, Pace University, New York, New York, United States of America
Jacob J. Plattner, Yvonne Freund, Charles Ding, Tsutomu Akama, Y.-K. Zhang
Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America
Reto Brun, Marcel Kaiser
Swiss Tropical and Public Health Institute, Basel, Switzerland
Ivan Scandale, Robert Don
Drugs for Neglected Diseases initiative, Geneva, Switzerland

Corresponding Author

Email: bob.jacobs@scynexis.com

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: RTJ BN SAW CJB NY RB RD. Performed the experiments: BN MDO DC JMS MXJ RAN TSB LTM CR EG JO RP RR BB MK. Analyzed the data: RTJ BN SAW MDO DC CJB NY JJP YF CD TA YKZ RB IS RD. Wrote the paper: RTJ BN SAW.